Stephen M. Ansell, MD, PhD and David Straus, MD
In this episode, “Evolving Frontline Strategies in Hodgkin Lymphoma”, Stephen M. Ansell, MD, PhD and David Straus, MD discuss emerging data for induction and maintenance therapy in patients with Hodgkin lymphoma (HL).
In 2018, brentuximab vedotin (BV) — a CD30-directed antibody-drug conjugate – was approved for upfront use with chemotherapy in classical HL. The new indication was based on results from ECHELON-1, which demonstrated improved progression-free survival with BV in combination with AVD (doxorubicin, vinblastine, and dacarbazine) compared with standard ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Current research is also exploring the role of immune checkpoint inhibitors in HL, and whether these agents can be introduced into frontline.